S. Sacks

D. Lyster, S. Sacks, H. Dougan, 1994, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.

F. Aoki, S. Shafran, F. Diaz-Mitoma, 1996, JAMA.

Current Recommendations for the Treatment of Genital Herpes

D. Leung, S. Sacks, 2000, Drugs.

New developments in the epidemiology, natural history and management of genital herpes.

A. Wald, L. Stanberry, A. Cunningham, 1999, Antiviral research.

Improving the management of genital herpes.

S. Sacks, 1999, Hospital practice.

A Multicenter Phase I/II Dose Escalation Study of Single-Dose Cidofovir Gel for Treatment of Recurrent Genital Herpes

S. Trottier, S. Shafran, F. Diaz-Mitoma, 1998, Antimicrobial Agents and Chemotherapy.

Famciclovir for Genital Herpes-Reply

S. Shafran, F. Diaz-Mitoma, S. Sacks, 1997 .

Chronic Suppression for Six Months Compared With Intermittent Lesional Therapy of Recurrent Genital Herpes Using Oral Acyclovir: Effects on Lesions and Nonlesional Prodromes

H. Stiver, R. Keeney, S. Sacks, 1988, Sexually transmitted diseases.

Treatment of Herpes Genitalis

S. Sacks, 1988 .

The role of oral acyclovir in the management of genital herpes simplex.

S. Sacks, 1987, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Serotyping of herpes simplex virus isolates: a comparison of BVDU sensitivities, indirect immunofluorescence with monoclonal antibodies, and indirect immunofluorescence with cross-adsorbed rabbit antibodies.

S. Sacks, C. Teh, L. Lemchuk-Favel, 1983, Journal of virological methods.

Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy.

T. Merigan, S. Sacks, I. Fox, 1982, The Journal of clinical investigation.

Comparative metabolism of E-5-(2-bromovinyl)-2'-deoxyuridine and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in herpes simplex virus-infected cells.

E. De Clercq, S. Sacks, R. J. Wanklin, 1987, Molecular pharmacology.

S. Manfredini, S. G. Wood, S. Sacks, 1991, Journal of medicinal chemistry.

Therapeutic use of newer antiviral agents.

S. Sacks, 1986, International journal of cell cloning.

Granulomatous Vaginal Ulceration due to Metastatic Cutaneous Crohn's Disease

Raymond Kwong, S. Sacks, H. Freeman, 1995 .

Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialie: a UK-based survey.

P. Crosson, S. Sacks, R. Boon, 2000, The Journal of antimicrobial chemotherapy.

Comparison of methods for identifying resistant herpes simplex virus and measuring antiviral susceptibility.

R. Sarisky, P. Crosson, S. Sacks, 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion?

J. Sasadeusz, S. Sacks, 1996, The Journal of infectious diseases.

New Antiherpesvirus Agents

F. Alrabiah, S. Sacks, 1996, Drugs.

Cytomegalovirus hepatitis: evidence for direct hepatic viral infection using monoclonal antibodies.

S. Sacks, H. Freeman, 1984, Gastroenterology.

Herpes simplex virus latency and nucleoside analogues.

P. Griffiths, L. Stanberry, H. Field, 1999, Antiviral research.

Current treatment options to prevent perinatal transmission of herpes simplex virus

D. Leung, S. Sacks, 2003, Expert opinion on pharmacotherapy.

Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial.

F. Aoki, S. Shafran, S. Sacks, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials

S. Tyring, S. Shafran, F. Diaz-Mitoma, 2003, Journal of cutaneous medicine and surgery.

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials

S. Tyring, S. Shafran, F. Diaz-Mitoma, 2003, Journal of cutaneous medicine and surgery.

Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis.

M. Lebwohl, J. Douglas, S. Sacks, 1992, Antiviral research.

Randomized, Double-Blind, Placebo-Controlled, Clinic-Initiated, Canadian Multicenter Trial of Topical Edoxudine 3.0% Cream in the Treatment of Recurrent Genital Herpes

J. Singer, F. Aoki, M. Gill, 1991 .

Topical undecylenic acid for herpes simplex labialis: a multicenter, placebo-controlled trial.

F. Aoki, D. Tyrrell, M. Gill, 1997, The Journal of infectious diseases.

Development and validation of a plasma assay for acyclovir using high-performance capillary electrophoresis with sample stacking.

D. Leung, S. Sacks, H. Vo, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding

F. Aoki, A. Wald, L. Corey, 2006, Sexually transmitted diseases.

Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial.

S. Sacks, 2004, The Journal of infectious diseases.

The synergistic effects of betulin with acyclovir against herpes simplex viruses.

S. Sacks, Robert Carlson, Stephen L Sacks, 2004, Antiviral research.

Quantitative description of analyte migration behavior based on the dynamic complexation model in capillary electrophoresis

D. D. Chen, S. Sacks, Xuejun Peng, 1997 .

A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B

P. Marcellin, B. Conway, G. Lau, 2004, Hepatology.

Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies.

M. Sherman, T. Wright, S. Sacks, 1998 .

Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

T. Merigan, W. Robinson, R. Pollard, 1981, The Journal of infectious diseases.

FAMCICLOVIR IN THE MANAGEMENT OF FIRST‐EPISODE GENITAL HERPES

M. Loveless, S. Sacks, J. W. Harris, 1997 .

Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination

T. Merigan, W. Robinson, R. Pollard, 1982, Antimicrobial Agents and Chemotherapy.

Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.

T. Mccarthy, B. Matthews, G. Holan, 2005, Antiviral research.

Section Review: Anti-infectives: Novel herpes treatments: A review

F. Alrabiah, S. Sacks, 1996 .

A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection

P. Marcellin, B. Conway, G. Lau, 2003 .

Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.

E. De Clercq, S. Spruance, S. Sacks, 1985, Antiviral research.

Randomized, double-blind, placebo-controlled, patient-initiated study of topical high-and low-dose interferon-α with nonoxynol-9 in the treatment of recurrent genital herpes

S. Sacks, Varner Tl, Davies Ks, 1990 .

Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.

F. Aoki, D. Tyrrell, W. Schlech, 1987, The Journal of infectious diseases.

Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2

S. Sacks, C. Teh, 1983, Antimicrobial Agents and Chemotherapy.

Lessons from HIV and hepatitis viruses.

S. Self, P. Griffiths, A. Wald, 2004, Antiviral research.

Metabolic fate of (E)-5-(2-bromovinyl)-2'-deoxyuridine in herpes simplex virus- and mock-infected cells

E. De Clercq, E. Clercq, S. Sacks, 1984, Antimicrobial Agents and Chemotherapy.

High-performance liquid chromatographic analysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine and its metabolites in serum, urine and herpes simplex virus type-1 infected cells.

E. De Clercq, S. Sacks, N. Ayisi, 1986, Journal of chromatography.

Differential metabolism of (E)-5-(2-bromovinyl)-2'-deoxyuridine in wild-type and drug-resistant herpes simplex virus-infected cells.

E. De Clercq, S. Sacks, N. Ayisi, 1985, Antiviral research.

Neurotoxic effects during vidarabine therapy for herpes zoster.

A. Chow, S. Sacks, D. Burdge, 1985, Canadian Medical Association journal.

Genital ulcers: their diagnosis and management.

S. Sacks, 1987, Canadian family physician Medecin de famille canadien.

Therapeutic options for herpes simplex infections

S. Sacks, E. Au, 2003, Current infectious disease reports.

Herpes latency, meningitis, radiculomyelopathy and disseminated infection.

J. Sasadeusz, S. Sacks, 1994, Genitourinary medicine.

Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial.

D. Katz, R. Thisted, J. Jorizzo, 2001, Journal of the American Academy of Dermatology.

A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery.

L. Corey, D. H. Watts, Meei-Li W Huang, 2003, American journal of obstetrics and gynecology.

Drug resistance in malaria: three cases and a review.

A. Chow, J. Isaac-Renton, S. Sacks, 1983, Canadian Medical Association journal.

HSV-2 transmission.

S. Self, P. Griffiths, A. Wald, 2004, Antiviral research.

New antiherpesvirus agents. Their targets and therapeutic potential.

F. Alrabiah, S. Sacks, 1996, Drugs.

Do antepartum herpes simplex virus cultures predict intrapartum shedding for pregnant women with recurrent disease?

T. N. Lee, S. Garland, S. Sacks, 1999, Infectious diseases in obstetrics and gynecology.

Infectious Aortitis due to Penicillin-Resistant Streptococcus pneumoniae

S. Sacks, A. Maclennan, D. Doyle, 1997, Annals of vascular surgery.

Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

F. Aoki, D. Bernstein, L. Stanberry, 2002, The New England journal of medicine.

Automated microneutralization: method and comparison with western blot for type-specific detection of herpes simplex antibodies in two pregnant populations.

T. N. Lee, L. Corey, S. Sacks, 1995, Journal of virological methods.

Amino acid analysis using 1-naphthylisocyanate as a precolumn high performance liquid chromatography derivatization reagent.

S. Sacks, M. Banay‐Schwartz, A. Neidle, 1989, Analytical Biochemistry.

Genital Herpes: The Epidemiology and Control of a Common Sexually Transmitted Disease

S. Sacks, M. Steben, 1997 .

Systemic lymphoblastoid interferon therapy in chronic progressive multiple Sclerosis. I. Clinical and MRI evaluation

A J Petkau, S L Sacks, D. Li, 1990, Neurology.

Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet.

D. Coen, E. Pelosi, S. Sacks, 1992, Advances in experimental medicine and biology.

Three Phase III Randomized Controlled Trials of Topical Resiquimod 0.01-Percent Gel To Reduce Anogenital Herpes Recurrences

A. Wald, A. Magaret, S. Selke, 2014, Antimicrobial Agents and Chemotherapy.

Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation

D. Paty, J. Oger, L. Kastrukoff, 1991, Neurology.

HSV shedding.

S. Self, P. Griffiths, A. Wald, 2004, Antiviral research.

Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.

F. Aoki, S. Shafran, F. Diaz-Mitoma, 1996, JAMA.

Sorivudine (BV-ara-U) for the treatment of complicated refractory varicella zoster virus infection in HIV-infected patients.

S. Sacks, D. Burdge, J. Lindley, 1995, AIDS.

Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy.

A. Wald, L. Corey, D. Leung, 2009, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV

P. Marcellin, B. Conway, G. Lau, 2003 .

Aseptic meningitis as a complication of scinticysternography utilizing 111indium-DTPA

G. Forster, N. Christoff, S. Sacks, 1975, Clinical Neurology and Neurosurgery.

Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group.

W. Rozenbaum, A. Rachlis, S. Danner, 1997, The Journal of infectious diseases.

A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo.

Richard J. T. Klein, H. Keyserling, A. Nahmias, 1984, The Journal of infectious diseases.

Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes.

E. DeLong, H. Stiver, S. Sacks, 1990, The Journal of infectious diseases.